No Data
RemeGen Co. Ltd. Class H (9995) Gets a Hold From J.P. Morgan
Hong Kong stock movement | REMEGEN (09995) drops 7% after earnings, with first-quarter revenue increasing nearly 60% year-on-year, and losses narrowing to 0.254 billion yuan.
REMEGEN (09995) fell by 7% after its earnings report. Notably, the stock had previously increased by more than double in the last month. As of the time of writing, it is down 7%, priced at 38.5 Hong Kong dollars, with a trading volume of 0.277 billion Hong Kong dollars.
Rongchang Biotech: Rongchang Biopharmaceutical (Yantai) Co., Ltd. Report for the first quarter of 2025
Rongchang Biopharmaceutical (Yantai) Co., Ltd. 2025 First Quarter Report
Express News | RemeGen - Qtrly Operating Revenue RMB526 Mln
REMEGEN: 2025 FIRST QUARTERLY REPORT
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up
